NASDAQ: NUVL
Nuvalent, Inc.
Healthcare · Biotechnology
Market Cap
$9.13B
52w High
$123.99
52w Low
$71.13
P/E
-20.46
Volume
0.00
Outstanding Shares
73.69M
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock rose 50.33% over the last year. Free cash flow declined 53.48% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
8
Buy
11
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 6, 2026
Q3 FY26 · EPS est -$1.44 · Revenue est $245.46K
View